Advertisement
Advertisement
MLTX
MoonLake Immunotherapeutics Class A Ordinary Shares
18.41
USDSponsored
+0.22
+1.21%
May 13, 16:00 UTC -4
Closed
After-Market
18.36
-0.05
-0.27%
MLTX Earnings Reports
Positive Surprise Ratio
MLTX beat 9 of 16 last estimates.
56%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.92
Implied change from Q1 26 (Revenue/ EPS)
--
/-6.12%
Implied change from Q2 25 (Revenue/ EPS)
--
/+5.75%
MoonLake Immunotherapeutics Class A Ordinary Shares earnings per share and revenue
On May 10, 2026, MLTX reported earnings of -0.98 USD per share (EPS) for Q1 26, missing the estimate of -0.90 USD, resulting in a -7.73% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.82% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of -0.92 USD, with revenue projected to reach -- USD, implying an decrease of -6.12% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were MoonLake Immunotherapeutics Class A Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, MoonLake Immunotherapeutics Class A Ordinary Shares reported EPS of -$0.98, missing estimates by -7.73%, and revenue of $0.00, 0% as expectations.
How did the market react to MoonLake Immunotherapeutics Class A Ordinary Shares's Q1 2026 earnings?
The stock price moved down -2.82%, changed from $17.70 before the earnings release to $17.20 the day after.
When is MoonLake Immunotherapeutics Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for MoonLake Immunotherapeutics Class A Ordinary Shares's next earnings report?
Based on 11
analysts, MoonLake Immunotherapeutics Class A Ordinary Shares is expected to report EPS of -$0.92 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement